BiotechTube

TXA127 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID-19

Conditions

COVID-19

Trial Timeline

Feb 10, 2021 → Jun 10, 2021

NCT ID
NCT04401423

About TXA127 + Placebo

TXA127 + Placebo is a phase 2 stage product being developed by Constant Therapeutics for COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT04401423. Target conditions include COVID-19.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04401423Phase 2Completed
NCT01121120Phase 2Terminated

Competing Products

20 competing products in COVID-19

See all competitors
ProductCompanyStageHype Score
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
DesidustatZydus LifesciencesPhase 2
52
LY3819253 + PlaceboEli LillyPhase 1
33
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + BebtelovimabEli LillyPhase 2
52
BamlanivimabEli LillyPhase 2
52
LY3127804 + PlaceboEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 3
77
BamlanivimabEli LillyPre-clinical
23
LY3819253 + Placebo + RemdesivirEli LillyPhase 3
77
LY3819253 + LY3832479 + LY3853113 + PlaceboEli LillyPhase 2/3
65

Other Products from Constant Therapeutics

TXA127 + PlaceboPhase 2
44
Angiotensin 1-7Phase 2
44
talfirastidePhase 2
44
talfirastide + PlaceboPhase 2
44
TXA127 300 mcg/kg/day + TXA127 1000 mcg/kg/dayPhase 1
25